BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 26755635)

  • 61. Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair.
    Haradhvala NJ; Polak P; Stojanov P; Covington KR; Shinbrot E; Hess JM; Rheinbay E; Kim J; Maruvka YE; Braunstein LZ; Kamburov A; Hanawalt PC; Wheeler DA; Koren A; Lawrence MS; Getz G
    Cell; 2016 Jan; 164(3):538-49. PubMed ID: 26806129
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Signatures of mutational processes in human cancer.
    Alexandrov LB; Nik-Zainal S; Wedge DC; Aparicio SA; Behjati S; Biankin AV; Bignell GR; Bolli N; Borg A; Børresen-Dale AL; Boyault S; Burkhardt B; Butler AP; Caldas C; Davies HR; Desmedt C; Eils R; Eyfjörd JE; Foekens JA; Greaves M; Hosoda F; Hutter B; Ilicic T; Imbeaud S; Imielinski M; Jäger N; Jones DT; Jones D; Knappskog S; Kool M; Lakhani SR; López-Otín C; Martin S; Munshi NC; Nakamura H; Northcott PA; Pajic M; Papaemmanuil E; Paradiso A; Pearson JV; Puente XS; Raine K; Ramakrishna M; Richardson AL; Richter J; Rosenstiel P; Schlesner M; Schumacher TN; Span PN; Teague JW; Totoki Y; Tutt AN; Valdés-Mas R; van Buuren MM; van 't Veer L; Vincent-Salomon A; Waddell N; Yates LR; ; ; ; ; Zucman-Rossi J; Futreal PA; McDermott U; Lichter P; Meyerson M; Grimmond SM; Siebert R; Campo E; Shibata T; Pfister SM; Campbell PJ; Stratton MR
    Nature; 2013 Aug; 500(7463):415-21. PubMed ID: 23945592
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The APOBEC-2 crystal structure and functional implications for the deaminase AID.
    Prochnow C; Bransteitter R; Klein MG; Goodman MF; Chen XS
    Nature; 2007 Jan; 445(7126):447-51. PubMed ID: 17187054
    [TBL] [Abstract][Full Text] [Related]  

  • 64. APOBEC mutagenesis is low in most types of non-B DNA structures.
    Ponomarev GV; Fatykhov B; Nazarov VA; Abasov R; Shvarov E; Landik NV; Denisova AA; Chervova AA; Gelfand MS; Kazanov MD
    iScience; 2022 Jul; 25(7):104535. PubMed ID: 35754742
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Monitoring APOBEC3A protein levels in human cancer cells.
    Dananberg A; Maciejowski J
    Methods Cell Biol; 2024; 182():313-327. PubMed ID: 38359985
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dancin' deaminase.
    Harris RS; Matsuo H
    Nat Struct Mol Biol; 2006 May; 13(5):380-1. PubMed ID: 16738602
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nucleotide Weight Matrices Reveal Ubiquitous Mutational Footprints of AID/APOBEC Deaminases in Human Cancer Genomes.
    Rogozin IB; Roche-Lima A; Lada AG; Belinky F; Sidorenko IA; Glazko GV; Babenko VN; Cooper DN; Pavlov YI
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30759888
    [TBL] [Abstract][Full Text] [Related]  

  • 68. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.
    Kanu N; Cerone MA; Goh G; Zalmas LP; Bartkova J; Dietzen M; McGranahan N; Rogers R; Law EK; Gromova I; Kschischo M; Walton MI; Rossanese OW; Bartek J; Harris RS; Venkatesan S; Swanton C
    Genome Biol; 2016 Sep; 17(1):185. PubMed ID: 27634334
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Enzymatic cytosine deamination: friend and foe.
    Kunkel TA; Diaz M
    Mol Cell; 2002 Nov; 10(5):962-3. PubMed ID: 12453402
    [No Abstract]   [Full Text] [Related]  

  • 70. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
    Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
    J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
    [TBL] [Abstract][Full Text] [Related]  

  • 71. APOBECs and Herpesviruses.
    Cheng AZ; Moraes SN; Shaban NM; Fanunza E; Bierle CJ; Southern PJ; Bresnahan WA; Rice SA; Harris RS
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33671095
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
    Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
    Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
    Matsumoto T; Shirakawa K; Yokoyama M; Fukuda H; Sarca AD; Koyabu S; Yamazaki H; Kazuma Y; Matsui H; Maruyama W; Nagata K; Tanabe F; Kobayashi M; Shindo K; Morishita R; Sato H; Takaori-Kondo A
    Sci Rep; 2019 Jun; 9(1):8307. PubMed ID: 31165764
    [TBL] [Abstract][Full Text] [Related]  

  • 74. APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types.
    Jakobsdottir GM; Brewer DS; Cooper C; Green C; Wedge DC
    BMC Biol; 2022 May; 20(1):117. PubMed ID: 35597990
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MicroRNAs regulate APOBEC gene expression.
    Cao W; Wu W
    Histol Histopathol; 2018 Feb; 33(2):117-120. PubMed ID: 28604942
    [TBL] [Abstract][Full Text] [Related]  

  • 76. APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
    Buisson R; Lawrence MS; Benes CH; Zou L
    Cancer Res; 2017 Sep; 77(17):4567-4578. PubMed ID: 28698210
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
    Li X; Wang Y; Deng S; Zhu G; Wang C; Johnson NA; Zhang Z; Tirado CR; Xu Y; Metang LA; Gonzalez J; Mukherji A; Ye J; Yang Y; Peng W; Tang Y; Hofstad M; Xie Z; Yoon H; Chen L; Liu X; Chen S; Zhu H; Strand D; Liang H; Raj G; He HH; Mendell JT; Li B; Wang T; Mu P
    Cancer Cell; 2023 Aug; 41(8):1427-1449.e12. PubMed ID: 37478850
    [TBL] [Abstract][Full Text] [Related]  

  • 78. APOBEC-Induced Mutagenesis in Cancer.
    Mertz TM; Collins CD; Dennis M; Coxon M; Roberts SA
    Annu Rev Genet; 2022 Nov; 56():229-252. PubMed ID: 36028227
    [TBL] [Abstract][Full Text] [Related]  

  • 79. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response.
    Glaser AP; Fantini D; Wang Y; Yu Y; Rimar KJ; Podojil JR; Miller SD; Meeks JJ
    Oncotarget; 2018 Jan; 9(4):4537-4548. PubMed ID: 29435122
    [TBL] [Abstract][Full Text] [Related]  

  • 80. APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable.
    Vile RG; Melcher A; Pandha H; Harrington KJ; Pulido JS
    Clin Cancer Res; 2021 Jun; 27(12):3280-3290. PubMed ID: 33558423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.